Neumora Therapeutics (NMRA) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 27, 2026, with voting open until May 26, 2026, at 11:59 PM ET.

• Shareholders can access proxy materials online or request paper/email copies by May 13, 2026.

• Meeting will be held virtually, allowing remote participation and voting.

Voting matters and shareholder proposals

• Election of three Class III directors to serve until the 2029 annual meeting or until successors are elected.

• Ratification of Ernst & Young LLP as independent auditor for the year ending December 31, 2026.

• Advisory vote on executive compensation (say-on-pay).

• Advisory vote on the frequency of future say-on-pay votes, with the board recommending an annual vote.

Board of directors and corporate governance

• Nominees for Class III director positions are Paul Berns, Matthew Fust, and David Piacquad.

• Board recommends voting in favor of all director nominees.